approved

Приложение 4 на ПЛС от 02.10.2020 г.

Unique identificator:  9c8162ef-5c30-4c3c-ae8b-09bec0f8f412

Description:

Приложение 4 на ПЛС от 02.10.2020 г.

РМС 214/2016

Current version: 2

Displayed version: 1

Format: CSV

  • Created at: 2020-10-05 14:44:21
  • Created by: georgi_sivchev
  • Updated at: 2020-10-15 10:22:27
  • Updated by: georgi_sivchev
records per page
Order by:

ПОЗИТИВЕН ЛЕКАРСТВЕН СПИСЪК

Doxorubicin EU/1/12/769/001EU/1/00/141/001 Myocet, Powder, dispersion and solvent for concentrate for dispersion for infusion, 50, mg, Pack: 2 Teva Pharma B.V., Нидерландия GP-Pharma Poligon Industrial Els Vinyets – Els Fogars, Sector 2, Carretera Comarcal C244, km22 08777 Sant Quinti de Mediona (Barcelona) Spain; Teva Operations Poland Sp. z o.o., ul. Mogilska 80, 31-546 1774.88 354.98 2129.86 4% 10 1784.88 356.98 2141.86 16% 25 1809.88 361.98 2171.86 промяна на осбстоятелства НСР-1009/16.08.2013 НСР-990/16.08.2013 04.09.2013 04.09.2013 Неактивен 3463
Doxorubicin EU/1/12/769/001EU/1/00/141/001 Myocet, Powder, dispersion and solvent for concentrate for dispersion for infusion, 50, mg, Pack: 2 Cephalon Europe, Франция GP-Pharma Poligon Industrial Els Vinyets – Els Fogars, Sector 2, Carretera Comarcal C244, km22 08777 Sant Quinti de Mediona (Barcelona) Spain; Teva Operations Poland Sp. z o.o., ul. Mogilska 80, 31-546 1865.16 373.03 2238.19 4% 10 1875.16 375.03 2250.19 16% 25 1900.16 380.03 2280.19 КЦРР-1702/27.11.2012 12.12.2012 12.12.2012 Неактивен 3463
Technetium [99mTc] tetrofosmin 20060671 Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) GE Healthcare AS, Норвегия GE Healthcare AS, Норвегия 1093.31 218.66 1311.97 4% 10 1103.31 220.66 1323.97 16% 25 1128.31 225.66 1353.97 НСР-20918/27.02.2020 промяна на обстоятелства; НСР-21440/07.05.2020 предварително изпълнение КЦ-823/15.04.2009 30.04.2009 02.07.2020 Активен 711
Technetium [99mTc] tetrofosmin 20060671 Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) GE Healthcare AS, Норвегия GE Healthcare AS, Норвегия 1093.31 218.66 1311.97 4% 10 1103.31 220.66 1323.97 16% 25 1128.31 225.66 1353.97 НСР-20918/27.02.2020 промяна на обстоятелства; НСР-21440/07.05.2020 предварително изпълнение** КЦ-823/15.04.2009 30.04.2009 02.06.2020 Неактивен 711
Technetium [99mTc] tetrofosmin II-15004/24.11.2006 Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) GE Healthcare AS, Норвегия GE Healthcare AS, Норвегия 1093.31 218.66 1311.97 4% 10 1103.31 220.66 1323.97 16% 25 1128.31 225.66 1353.97 НСР-20918/27.02.2020 промяна на обстоятелства КЦ-823/15.04.2009 30.04.2009 02.04.2020 Неактивен 711
Technetium [99mTc] tetrofosmin II-15004/24.11.2006 Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) GE Healthcare Ltd, Обединено Кралство GE Healthcare Limited 1093.31 218.66 1311.97 4% 10 1103.31 220.66 1323.97 16% 25 1128.31 225.66 1353.97 КЦ-823/15.04.2009 30.04.2009 30.04.2009 Неактивен 711
Technetium [99mTc] tetrofosmin II-15004/24.11.2006 Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) GE Healthcare Ltd, Обединено Кралство GE Healthcare Limited 1093.31 218.66 1311.97 4% 10 1103.31 220.66 1323.97 16% 25 1128.31 225.66 1353.97 КЦ-823/15.04.2009 30.04.2009 30.04.2009 Неактивен 711
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK; Genzyme Ireland Ltd., Ирландия 790.68 158.14 948.82 4% 10 800.68 160.14 960.82 16% 25 825.68 165.14 990.82 Промяна на обстоятелства НСР-19627/21.08.2019 НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017; НСР-15921/15.06.2018 30.06.2018 02.10.2019 Активен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK; Genzyme Ireland Ltd., Ирландия 790.68 158.14 948.82 4% 10 800.68 160.14 960.82 16% 25 825.68 165.14 990.82 Промяна на обстоятелства НСР-19627/21.08.2019 НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017; НСР-15921/15.06.2018 30.06.2018 02.10.2019 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK 790.68 158.14 948.82 4% 10 800.68 160.14 960.82 16% 25 825.68 165.14 990.82 НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017; НСР-15921/15.06.2018 30.06.2018 02.07.2018 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK 807.91 161.58 969.49 4% 10 817.91 163.58 981.49 16% 25 842.91 168.58 1011.49 НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017 28.10.2017 02.11.2017 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK 828.06 165.61 993.67 4% 10 838.06 167.61 1005.67 16% 25 863.06 172.61 1035.67 НСР-8521/16.03.2016; НСР-10987/24.11.2016 02.01.2017 02.01.2017 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK 832.99 166.6 999.59 4% 10 842.99 168.6 1011.59 16% 25 867.99 173.6 1041.59 НСР-8521/16.03.2016 31.03.2016 31.03.2016 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK 832.99 166.6 999.59 4% 10 842.99 168.6 1011.59 16% 25 867.99 173.6 1041.59 НСР-8521/16.03.2016 31.03.2016 31.03.2016 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK 838.58 167.72 1006.3 4% 10 848.58 169.72 1018.3 16% 25 873.58 174.72 1048.3 НСР-6598/01.07.2015 17.07.2015 17.07.2015 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd., UK 844.06 168.81 1012.87 4% 10 854.06 170.81 1024.87 16% 25 879.06 175.81 1054.87 НСР-4936/22.10.2014 06.11.2014 06.11.2014 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd. UK 862.15 172.43 1034.58 4% 10 872.15 174.43 1046.58 16% 25 897.15 179.43 1076.58 корекц. Решение НСР-3158/26.03.2014 НСР-2771/17.02.2014 06.03.2014 06.03.2014 Неактивен 3264
Alglucosidase alfa EU/1/06/333/001-003 Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 Genzyme Europe B.V., Нидерландия Genzyme Ltd. UK 916.27 183.25 1099.52 4% 10 926.27 185.25 1111.52 16% 25 951.27 190.25 1141.52 HCР-18/31.05.2013 02.06.2013 02.06.2013 Неактивен 3264
Galsulfase EU/1/05/324/001 Naglazyme, Concentrate for solution for infusion, 1mg/ml, 5 ml, Pack: 1 BioMarin Europe Limited, Обединено Кралство Catalent UK Packaging Ltd, Великобритания 2543.38 508.68 3052.06 4% 10 2553.38 510.68 3064.06 16% 25 2578.38 515.68 3094.06 корекционно решение НСР-6891/30.07.2015; цената е вписана в регистъра на пределните цени с решение НСР-7947/08.02.2016 г.(в сила от 02.03.2016) НСР-6483/18.06.2015 04.07.2015 04.07.2015 Заличен 3285
Galsulfase EU/1/05/324/001 Naglazyme, Concentrate for solution for infusion, 1mg/ml, 5 ml, Pack: 1 BioMarin Europe Limited, Обединено Кралство Catalent UK Packaging Ltd, Великобритания 2630.06 526.01 3156.07 4% 10 2640.06 528.01 3168.07 16% 25 2665.06 533.01 3198.07 НСР-4918/22.10.2014 06.11.2014 06.11.2014 Неактивен 3285
Galsulfase EU/1/05/324/001 Naglazyme, Concentrate for solution for infusion, 1mg/ml, 5 ml, Pack: 1 BioMarin Europe Limited, Обединено Кралство Catalent UK Packaging Ltd, Великобритания 2684.87 536.97 3221.84 4% 10 2694.87 538.97 3233.84 16% 25 2719.87 543.97 3263.84 НСР-1027/23.08.2013 09.09.2013 09.09.2013 Неактивен 3285
Diclofenac 20030384 Naklofen, Solution for injection, 75 mg/3 ml, -, Pack: 5 KRKA, d.d., Словения KRKA, d.d. Novo Mesto, Slovenia 2.56 0.51 3.07 7% 0.18 2.74 0.55 3.29 20% 0.51 3.25 0.65 3.9 промяна на обстоятелства НСР-10708/21.10.2016 НСР-558/23.07.2013;; НСР-21326/23.04.2020 Предварително изпълнение 23.04.2020 02.07.2020 Активен 2055
Diclofenac 20030384 Naklofen, Solution for injection, 75 mg/3 ml, -, Pack: 5 KRKA, d.d., Словения KRKA, d.d. Novo Mesto, Slovenia 2.56 0.51 3.07 7% 0.18 2.74 0.55 3.29 20% 0.51 3.25 0.65 3.9 промяна на обстоятелства НСР-10708/21.10.2016 НСР-558/23.07.2013; НСР-21326/23.04.2020 Предварително изпълнение** 23.04.2020 02.05.2020 Неактивен 2055
Diclofenac 20030384 Naklofen, Solution for injection, 75 mg/3 ml, mg, Pack: 5 KRKA, d.d., Словения KRKA, d.d. Novo Mesto, Slovenia 1.9 0.38 2.28 7% 0.13 2.03 0.41 2.44 20% 0.38 2.41 0.48 2.89 промяна на обстоятелства НСР-10708/21.10.2016 НСР-558/23.07.2013 04.09.2013 02.12.2016 Неактивен 2055
Diclofenac 20030384 Naklofen, Solution for injection, 75 mg/3 ml, mg, Pack: 5 KRKA, d.d., Словения KRKA, d.d. Novo Mesto, Slovenia 1.9 0.38 2.28 7% 0.13 2.03 0.41 2.44 20% 0.38 2.41 0.48 2.89 промяна на обстоятелства НСР-10708/21.10.2016 НСР-558/23.07.2013 04.09.2013 02.12.2016 Неактивен 2055
Showing 10101 to 10126 of 17975 entries
Download link in CSV format: Copy
Download link in JSON format: Copy
Download link in XML format: Copy
 

Моля изчакайте